Vico Therapeutics Announces $60 million (54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington's disease
Financing led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partner... Biopharmaceuticals, Neurology, Venture Capital Vico Therapeutics, spinocerebellar ataxia, Huntington's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Ataxia | Brain | Clinical Trials | Funding | Huntington's Disease | Neurology | Pharmaceuticals | Venture Capital